chronic myelogenous leukemia cancer cell lines k562  (ATCC)

Journal: Cell Reports Medicine

Article Title: Development of allogeneic HSC-engineered iNKT cells for off-the-shelf cancer immunotherapy

doi: 10.1016/j.xcrm.2021.100449

Figure Lengend Snippet: Tumor targeting of Allo HSC-iNKT cells through intrinsic NK function (A and B) FACS analyses of surface NK receptor expression and intracellular cytotoxic molecule production by Allo HSC-iNKT cells. PBMC-NK cells were included as a control. (A) Representative FACS plots. (B) Quantification of (A) (n = 9). (C–E) In vitro direct killing of human tumor cells by Allo HSC-iNKT cells. PBMC-NK cells were included as a control. Both fresh and frozen-thawed cells were studied. Five human tumor cell lines were studied: A375 (melanoma), K562 (myelogenous leukemia), H292 (lung cancer), PC3 (prostate cancer), and MM.1S (multiple myeloma). All tumor cell lines were engineered to express firefly luciferase and green fluorescence protein (FG) dual reporters. (C) Experimental design. (D and E) Tumor killing data of A375-FG human melanoma cells (D) and K562-FG human myelogenous leukemia cells (E) at 24 h (n = 4). (F–H) Tumor killing mechanisms of Allo HSC-iNKT cells. NKG2D- and DNAM-1-mediated pathways were studied. (F) Experimental design. (G) Tumor killing data of A375-FG human melanoma cells at 24 h (tumor/iNKT ratio 1:2; n = 4). (H) Tumor killing data of K562-FG human myelogenous leukemia cells at 24 h (tumor/iNKT ratio 1:1; n = 4). (I–K) Studying the in vivo antitumor efficacy of Allo HSC-iNKT cells in an A375-FG human melanoma xenograft NSG mouse model. (I) Experimental design. BLI, live animal bioluminescence imaging. (J) BLI images showing tumor loads in experimental mice over time. (K) Tumor size measurements over time (n = 4–5). Representative of three experiments. Data are presented as the mean ± SEM. ns, not significant; ∗p < 0.05; ∗∗p < 0.01; ∗∗∗p < 0.001; ∗∗∗∗p < 0.0001 by Student’s t test (B) or one-way ANOVA (D, E, G, H, and K). See also Figure S1 .

Article Snippet: Human chronic myelogenous leukemia cancer cell line K562 , ATCC , CCL-243.

Techniques: Expressing, Control, In Vitro, Luciferase, Fluorescence, In Vivo, Imaging

Journal: Cell Reports Medicine

Article Title: Development of allogeneic HSC-engineered iNKT cells for off-the-shelf cancer immunotherapy

doi: 10.1016/j.xcrm.2021.100449

Figure Lengend Snippet:

Article Snippet: Human chronic myelogenous leukemia cancer cell line K562 , ATCC , CCL-243.

Techniques: Enzyme-linked Immunosorbent Assay, Blocking Assay, Purification, Control, Virus, Recombinant, Cell Culture, Saline, Cell Isolation, RNA Sequencing, Gene Expression, Sequencing, Derivative Assay, Plasmid Preparation, Software, Imaging

Journal: Cell Reports Medicine

Article Title: Development of allogeneic HSC-engineered iNKT cells for off-the-shelf cancer immunotherapy

doi: 10.1016/j.xcrm.2021.100449

Figure Lengend Snippet: Tumor targeting of Allo HSC-iNKT cells through intrinsic NK function (A and B) FACS analyses of surface NK receptor expression and intracellular cytotoxic molecule production by Allo HSC-iNKT cells. PBMC-NK cells were included as a control. (A) Representative FACS plots. (B) Quantification of (A) (n = 9). (C–E) In vitro direct killing of human tumor cells by Allo HSC-iNKT cells. PBMC-NK cells were included as a control. Both fresh and frozen-thawed cells were studied. Five human tumor cell lines were studied: A375 (melanoma), K562 (myelogenous leukemia), H292 (lung cancer), PC3 (prostate cancer), and MM.1S (multiple myeloma). All tumor cell lines were engineered to express firefly luciferase and green fluorescence protein (FG) dual reporters. (C) Experimental design. (D and E) Tumor killing data of A375-FG human melanoma cells (D) and K562-FG human myelogenous leukemia cells (E) at 24 h (n = 4). (F–H) Tumor killing mechanisms of Allo HSC-iNKT cells. NKG2D- and DNAM-1-mediated pathways were studied. (F) Experimental design. (G) Tumor killing data of A375-FG human melanoma cells at 24 h (tumor/iNKT ratio 1:2; n = 4). (H) Tumor killing data of K562-FG human myelogenous leukemia cells at 24 h (tumor/iNKT ratio 1:1; n = 4). (I–K) Studying the in vivo antitumor efficacy of Allo HSC-iNKT cells in an A375-FG human melanoma xenograft NSG mouse model. (I) Experimental design. BLI, live animal bioluminescence imaging. (J) BLI images showing tumor loads in experimental mice over time. (K) Tumor size measurements over time (n = 4–5). Representative of three experiments. Data are presented as the mean ± SEM. ns, not significant; ∗p < 0.05; ∗∗p < 0.01; ∗∗∗p < 0.001; ∗∗∗∗p < 0.0001 by Student’s t test (B) or one-way ANOVA (D, E, G, H, and K). See also Figure S1 .

Article Snippet: Human multiple myeloma cancer cell line MM.1S, chronic myelogenous leukemia cancer cell line K562, melanoma cell line A375, lung carcinoma cell line H292, and prostate cancer cell line PC3 were purchased from the American Type Culture Collection (ATCC).

Techniques: Expressing, Control, In Vitro, Luciferase, Fluorescence, In Vivo, Imaging

Journal: Cell Reports Medicine

Article Title: Development of allogeneic HSC-engineered iNKT cells for off-the-shelf cancer immunotherapy

doi: 10.1016/j.xcrm.2021.100449

Figure Lengend Snippet:

Article Snippet: Human multiple myeloma cancer cell line MM.1S, chronic myelogenous leukemia cancer cell line K562, melanoma cell line A375, lung carcinoma cell line H292, and prostate cancer cell line PC3 were purchased from the American Type Culture Collection (ATCC).

Techniques: Enzyme-linked Immunosorbent Assay, Blocking Assay, Purification, Control, Virus, Recombinant, Cell Culture, Saline, Cell Isolation, RNA Sequencing, Gene Expression, Sequencing, Derivative Assay, Plasmid Preparation, Software, Imaging